VCYTVeracyte, Inc.

$3B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$92M+27.9% YoY

Gross Profit

$59M64.0% margin

Operating Income

-$22M-24.2% margin

Net Income

-$23M-25.0% margin

EPS (Diluted)

$-0.62

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$15M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$121M

Total Liabilities

$41M

Stockholders' Equity

$80M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$92M	$72M	+27.9%
Gross Profit	$59M	$44M	+34.7%
Operating Income	-$22M	-$27M	+16.2%
Net Income	-$23M	-$31M	+25.8%

VCYT FY 2018 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena